MedTrace Logo

Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.

NCT04413149 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-05-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the clinical features and long-term outcome of anti-neutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD) and assess the difference between microscopic polyangiitis (MPA) associated ILD and isolated ANCA-positive idiopathic interstitial pneumonia.

Conditions

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Juhong Shi, M.D · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-01
Primary Completion
2019-04-01
Completion
2020-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04413149 on ClinicalTrials.gov